Emerging therapeutic strategies for Epstein-Barr virus+ post-transplant lymphoproliferative disorder

Pediatric Transplantation

Volumn 16, Issue 3, 2012, Pages 220-229

  Hatton, Olivia ^a   Martinez, Olivia M ^a   Esquivel, Carlos O ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

B cell; Epstein Barr virus; post transplant lymphoproliferative disorder

Indexed keywords

4 DIALLYLAMINOMETHYLENE 1,3,4,7,10,11,12,13,14,15,16,17 DODECAHYDRO 6 HYDROXY 1 METHOXYMETHYL 10,13 DIMETHYL 3,7,17 TRIOXO 2 OXACYCLOPENTA[A]PHENANTHREN 11 YL ACETATE; ALPHA INTERFERON; BORTEZOMIB; CAL 101; CALCINEURIN INHIBITOR; CD40 ANTIGEN; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DOXORUBICIN; FLICE INHIBITORY PROTEIN; FOSTAMATINIB; GANCICLOVIR; IMMUNOGLOBULIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; METHOTREXATE; METHOXSALEN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 12; MITOGEN ACTIVATED PROTEIN KINASE KINASE 4; PICTRELISIB; PREDNISONE; PROTEIN BCL 2; PROTEIN KINASE B; RAPAMYCIN; RITUXIMAB; SYNAPTOPHYSIN; TACROLIMUS; THYMIDINE KINASE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED DEATH DOMAIN PROTEIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VINCRISTINE; XL 147;

ADRENAL DISEASE; CARBOXY TERMINAL SEQUENCE; CARDIOGENIC SHOCK; CELL DIFFERENTIATION; DRUG MEGADOSE; DRUG WITHDRAWAL; EPSTEIN BARR VIRUS; HEART ARRHYTHMIA; HEPATITIS C; HUMAN; LARGE CELL LYMPHOMA; LOW DRUG DOSE; LYMPHOMA; LYMPHOPROLIFERATIVE DISEASE; MONONUCLEOSIS; MULTIPLE ORGAN FAILURE; RETROSPECTIVE STUDY; REVIEW; SURVIVAL; TUMOR;

B-LYMPHOCYTES; GENE EXPRESSION REGULATION, VIRAL; GRAFT SURVIVAL; HERPESVIRUS 4, HUMAN; HUMANS; IMMUNOSUPPRESSIVE AGENTS; IMMUNOTHERAPY; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LYMPHOMA, B-CELL; LYMPHOPROLIFERATIVE DISORDERS; MODELS, BIOLOGICAL; ORGAN TRANSPLANTATION; PHOSPHATIDYLINOSITOL 3-KINASES; POSTOPERATIVE COMPLICATIONS; PROTEIN-TYROSINE KINASES; VIRAL MATRIX PROTEINS;

EID: 84859712855     PISSN: 13973142     EISSN: 13993046     Source Type: Journal    
DOI: 10.1111/j.1399-3046.2012.01656.x     Document Type: Review

References (116)

1. Young LS, Rickinson AB,. Epstein-Barr virus: 40 years on. Nat Rev Cancer 2004: 4: 757-768.
2. Snow AL, Martinez OM,. Epstein-Barr virus: Evasive maneuvers in the development of PTLD. Am J Transplant 2007: 7: 271-277.
3. Penn I,. Cancers complicating organ transplantation. N Engl J Med 1990: 323: 1767-1769.
4. Gottschalk S, Rooney CM, Heslop HE,. Post-transplant lymphoproliferative disorders. Annu Rev Med 2005: 56: 29-44.
5. Ho M,. Risk factors and pathogenesis of posttransplant lymphoproliferative disorders. Transplant Proc 1995: 27: 38-40.
6. Allen U, Hébert D, Moore D, et al., Epstein-Barr virus-related post-transplant lymphoproliferative disease in solid organ transplant recipients, 1988-97: A Canadian multi-centre experience. Pediatr Transplant 2001: 5: 198-203.
7. Gonzalez-Barca E, Domingo-Domenech E, Gomez-Codina J,. Firstline treatment with rituximab improves survival of patients with posttransplant lymphoproliferative disease (PTLD) [abstract]. Blood 2004: 104: 39a.
8. Paya CV, Fung JJ, Nalesnik MA, et al., Epstein-Barr virus-induced posttransplant lymphoproliferative disorders. ASTS/ASTP EBV-PTLD Task Force and The Mayo Clinic Organized International Consensus Development Meeting. Transplantation 1999: 68: 1517-1525.
9. McDonald R, Smith J, Ho M,. Incidence of PTLD in pediatric renal transplant recipients receiving basiliximab, calcineurin inhibitor, sirolimus and steroids. Am J Transplant 2008: 8: 984-989.
10. Dharnidharka VR, Martz KL, Stablein DM, et al., Improved survival with recent post-transplant lymphoproliferative disorder (PTLD) in children with kidney transplants. Am J Transplant 2011: 11: 751-758.
11. Tsai DE, Hardy CL, Tomaszewski JE, et al., Reduction in immunosuppression as initial therapy for posttransplant lymphoproliferative disorder: Analysis of prognostic variables and long-term follow-up of 42 adult patients. Transplantation 2001: 71: 1076-1088.
12. Hurwitz M, Desai DM, Cox KL, et al., Complete immunosuppressive withdrawal as a uniform approach to post-transplant lymphoproliferative disease in pediatric liver transplantation. Pediatr Transplant 2004: 8: 267-272.
13. Nepomuceno RR, Balatoni CE, Natkunam Y, et al., Rapamycin inhibits the interleukin 10 signal transduction pathway and the growth of Epstein Barr virus B-cell lymphomas. Cancer Res 2003: 63: 4472-4480.
14. Mathew T, Kreis H, Friend P,. Two-year incidence of malignancy in sirolimus-treated renal transplant recipients: Results from five multicenter studies. Clin Transplant 2004: 18: 446-449.
15. Oertel SH, Ruhnke MS, Anagnostopoulos I, et al., Treatment of Epstein-Barr virus-induced posttransplantation lymphoproliferative disorder with foscarnet alone in an adult after simultaneous heart and renal transplantation. Transplantation 1999: 67: 765-767.
16. Schaar CG, Van Der Pijl JW, Van HoekB, et al., Successful outcome with a "quintuple approach" of posttransplant lymphoproliferative disorder. Transplantation 2001: 71: 47-52.
17. Smets F, Vajro P, Cornu G, et al., Indications and results of chemotherapy in children with posttransplant lymphoproliferative disease after liver transplantation. Transplantation 2000: 69: 982-984.
18. Gross TG, Bucuvalas JC, Park JR, et al., Low-dose chemotherapy for Epstein-Barr virus-positive post-transplantation lymphoproliferative disease in children after solid organ transplantation. J Clin Oncol 2005: 23: 6481-6488.
19. Swinnen LJ, Mullen GM, Carr TJ, et al., Aggressive treatment for postcardiac transplant lymphoproliferation. Blood 1995: 86: 3333-3340.
20. Snanoudj R, Durrbach A, Leblond V, et al., Primary brain lymphomas after kidney transplantation: Presentation and outcome. Transplantation 2003: 76: 930-937.
21. Twist C, Kjelson L, McKenney A, et al., Treatment of recurrent post-transplant lymphoproliferative disorder (PTLD) of the central mervous system (CNS) with high-dose methotrexate (HD-MTX). Medimond International Proceedings 2009: 111.
22. Choquet S, Leblond V, Herbrecht R, et al., Efficacy and safety of rituximab in B-cell post-transplantation lymphoproliferative disorders: Results of a prospective multicenter phase 2 study. Blood 2006: 107: 3053-3057.
23. Elstrom RL, Andreadis C, Aqui NA, et al., Treatment of PTLD with rituximab or chemotherapy. Am J Transplant 2006: 6: 569-576.
24. Gupta S, Fricker FJ, González-Peralta RP, et al., Post-transplant lymphoproliferative disorder in children: Recent outcomes and response to dual rituximab/low-dose chemotherapy combination. Pediatr Transplant 2010: 14: 896-902.
25. Solak Y, Atalay H, Anil M, et al., Cost of paid transplantation abroad: Possible donor-origin early multiple myeloma in a renal transplant recipient treated using bortezomib. Transplant Proc 2010: 42: 2813-2815.
26. Benkerrou M, Jais JP, Leblond V, et al., Anti-B-cell monoclonal antibody treatment of severe posttransplant B-lymphoproliferative disorder: Prognostic factors and long-term outcome. Blood 1998: 92: 3137-3147.
27. Trappe R, Riess H, Babel N, et al., Salvage chemotherapy for refractory and relapsed posttransplant lymphoproliferative disorders (PTLD) after treatment with single-agent rituximab. Transplantation 2007: 83: 912-918.
28. Davis CL, Wood BL, Sabath DE, et al., Interferon-alpha treatment of posttransplant lymphoproliferative disorder in recipients of solid organ transplants. Transplantation 1998: 66: 1770-1779.
29. Nalesnik MA, Rao AS, Furukawa H, et al., Autologous lymphokine-activated killer cell therapy of Epstein-Barr virus-positive and -negative lymphoproliferative disorders arising in organ transplant recipients. Transplantation 1997: 63: 1200-1205.
30. Brewin J, Mancao C, Straathof K, et al., Generation of EBV-specific cytotoxic T cells that are resistant to calcineurin inhibitors for the treatment of posttransplantation lymphoproliferative disease. Blood 2009: 114: 4792-4803.
31. Schoch OD, Boehler A, Speich R, et al., Extracorporeal photochemotherapy for Epstein-Barr virus-associated lymphoma after lung transplantation. Transplantation 1999: 68: 1056-1058.
32. Majewski M, Korecka M, Kossev P, et al., The immunosuppressive macrolide RAD inhibits growth of human Epstein-Barr virus-transformed B lymphocytes in vitro and in vivo: A potential approach to prevention and treatment of posttransplant lymphoproliferative disorders. Proc Natl Acad Sci USA 2000: 97: 4285-4290.
33. Thorley-Lawson DA,. Epstein-Barr virus: Exploiting the immune system. Nat Rev Immunol 2001: 1: 75-82.
34. Babcock GJ, Hochberg D, Thorley-Lawson AD,. The expression pattern of Epstein-Barr virus latent genes in vivo is dependent upon the differentiation stage of the infected B cell. Immunity 2000: 13: 497-506.
35. Miller CL, Burkhardt AL, Lee JH, et al., Integral membrane protein 2 of Epstein-Barr virus regulates reactivation from latency through dominant negative effects on protein-tyrosine kinases. Immunity 1995: 2: 155-166.
36. Caldwell RG, Wilson JB, Anderson SJ, et al., Epstein-Barr virus LMP2A drives B cell development and survival in the absence of normal B cell receptor signals. Immunity 1998: 9: 405-411.
37. Dykstra ML, Longnecker R, Pierce SK,. Epstein-Barr virus coopts lipid rafts to block the signaling and antigen transport functions of the BCR. Immunity 2001: 14: 57-67.
38. Kilger E, Kieser A, Baumann M, et al., Epstein-Barr virus-mediated B-cell proliferation is dependent upon latent membrane protein 1, which simulates an activated CD40 receptor. EMBO J 1998: 17: 1700-1709.
39. Babcock GJ, Thorley-Lawson DA,. Tonsillar memory B cells, latently infected with Epstein-Barr virus, express the restricted pattern of latent genes previously found only in Epstein-Barr virus-associated tumors. Proc Natl Acad Sci USA 2000: 97: 12250-12255.
40. Wang D, Liebowitz D, Kieff E,. An EBV membrane protein expressed in immortalized lymphocytes transforms established rodent cells. Cell 1985: 43: 831-840.
41. Kaye KM, Izumi KM, Kieff E,. Epstein-Barr virus latent membrane protein 1 is essential for B-lymphocyte growth transformation. Proc Natl Acad Sci USA 1993: 90: 9150-9154.
42. Mosialos G, Birkenbach M, Yalamanchili R, et al., The Epstein-Barr virus transforming protein LMP1 engages signaling proteins for the tumor necrosis factor receptor family. Cell 1995: 80: 389-399.
43. Gires O, Zimber-Strobl U, Gonnella R, et al., Latent membrane protein 1 of Epstein-Barr virus mimics a constitutively active receptor molecule. EMBO J 1997: 16: 6131-6140.
44. Uchida J, Yasui T, Takaoka-Shichijo Y, et al., Mimicry of CD40 signals by Epstein-Barr virus LMP1 in B lymphocyte responses. Science 1999: 286: 300-303.
45. Henderson S, Rowe M, Gregory C, et al., Induction of bcl-2 expression by Epstein-Barr virus latent membrane protein 1 protects infected B cells from programmed cell death. Cell 1991: 65: 1107-1115.
46. Laherty CD, Hu HM, Opipari AW, et al., The Epstein-Barr virus LMP1 gene product induces A20 zinc finger protein expression by activating nuclear factor kappa B. J Biol Chem 1992: 267: 24157-24160.
47. Snow AL, Lambert SL, Natkunam Y, et al., EBV can protect latently infected B cell lymphomas from death receptor-induced apoptosis. J Immunol 2006: 177: 3283-3293.
48. Lambert SL, Martinez OM,. Latent membrane protein 1 of EBV activates phosphatidylinositol 3-kinase to induce production of IL-10. J Immunol 2007: 179: 8225-8234.
49. Devergne O, Hatzivassiliou E, Izumi KM, et al., Association of TRAF1, TRAF2, and TRAF3 with an Epstein-Barr virus LMP1 domain important for B-lymphocyte transformation: Role in NF-kappaB activation. Mol Cell Biol 1996: 16: 7098-7108.
50. Eliopoulos AG, Blake SM, Floettmann JE, et al., Epstein-Barr virus-encoded latent membrane protein 1 activates the JNK pathway through its extreme C terminus via a mechanism involving TRADD and TRAF2. J Virol 1999: 73: 1023-1035.
51. Gires O, Kohlhuber F, Kilger E, et al., Latent membrane protein 1 of Epstein-Barr virus interacts with JAK3 and activates STAT proteins. EMBO J 1999: 18: 3064-3073.
52. Mitchell T, Sugden B,. Stimulation of NF-kappa B-mediated transcription by mutant derivatives of the latent membrane protein of Epstein-Barr virus. J Virol 1995: 69: 2968-2976.
53. Dawson CW, Tramountanis G, Eliopoulos AG, et al., Epstein-Barr virus latent membrane protein 1 (LMP1) activates the phosphatidylinositol 3-kinase/Akt pathway to promote cell survival and induce actin filament remodeling. J Biol Chem 2003: 278: 3694-3704.
54. Mainou BA, Everly DNJ, Raab-Traub N,. Epstein-Barr virus latent membrane protein 1 CTAR1 mediates rodent and human fibroblast transformation through activation of PI3K. Oncogene 2005: 24: 6917-6924.
55. Caldwell RG, Brown RC, Longnecker R,. Epstein-Barr virus LMP2A-induced B-cell survival in two unique classes of EmuLMP2A transgenic mice. J Virol 2000: 74: 1101-1113.
56. Scholle F, Bendt KM, Raab-Traub N,. Epstein-Barr virus LMP2A transforms epithelial cells, inhibits cell differentiation, and activates Akt. J Virol 2000: 74: 10681-10689.
57. Mancao C, Hammerschmidt W,. Epstein-Barr virus latent membrane protein 2A is a B-cell receptor mimic and essential for B-cell survival. Blood 2007: 110: 3715-3721.
58. Morrison JA, Raab-Traub N,. Roles of the ITAM and PY motifs of Epstein-Barr virus latent membrane protein 2A in the inhibition of epithelial cell differentiation and activation of {beta}-catenin signaling. J Virol 2005: 79: 2375-2382.
59. Fruehling S, Longnecker R,. The immunoreceptor tyrosine-based activation motif of Epstein-Barr virus LMP2A is essential for blocking BCR-mediated signal transduction. Virology 1997: 235: 241-251.
60. Matskova L, Ernberg I, Pawson T, et al., C-terminal domain of the Epstein-Barr virus LMP2A membrane protein contains a clustering signal. J Virol 2001: 75: 10941-10949.
61. Longnecker R, Miller CL,. Regulation of Epstein-Barr virus latency by latent membrane protein 2. Trends Microbiol 1996: 4: 38-42.
62. Miller CL, Lee JH, Kieff E, et al., An integral membrane protein (LMP2) blocks reactivation of Epstein-Barr virus from latency following surface immunoglobulin crosslinking. Proc Natl Acad Sci USA 1994: 91: 772-776.
63. Portis T, Longnecker R,. Epstein-Barr virus (EBV) LMP2A mediates B-lymphocyte survival through constitutive activation of the Ras/PI3K/Akt pathway. Oncogene 2004: 23: 8619-8628.
64. Merchant M, Caldwell RG, Longnecker R,. The LMP2A ITAM is essential for providing B cells with development and survival signals in vivo. J Virol 2000: 74: 9115-9124.
65. Merlo A, Turrini R, Dolcetti R, et al., Adoptive cell therapy against EBV-related malignancies: A survey of clinical results. Expert Opin Biol Ther 2008: 8: 1265-1294.
66. Monroe JG,. ITAM-mediated tonic signalling through pre-BCR and BCR complexes. Nat Rev Immunol 2006: 6: 283-294.
67. Lam KP, Kuhn R, Rajewsky K,. In vivo ablation of surface immunoglobulin on mature B cells by inducible gene targeting results in rapid cell death. Cell 1997: 90: 1073-1083.
68. Kraus M, Alimzhanov MB, Rajewsky N, et al., Survival of resting mature B lymphocytes depends on BCR signaling via the Igalpha/beta heterodimer. Cell 2004: 117: 787-800.
69. Meffre E, Nussenzweig MC,. Deletion of immunoglobulin beta in developing B cells leads to cell death. Proc Natl Acad Sci USA 2002: 99: 11334-11339.
70. Kuppers R,. Mechanisms of B-cell lymphoma pathogenesis. Nat Rev Cancer 2005: 5: 251-262.
71. Gururajan M, Jennings CD, Bondada S,. Cutting edge: Constitutive B cell receptor signaling is critical for basal growth of B lymphoma. J Immunol 2006: 176: 5715-5719.
72. Hatton O, Phillips LK, Vaysberg M, et al., Syk activation of phosphatidylinositol 3-kinase/Akt prevents HtrA2-dependent loss of X-linked inhibitor of apoptosis protein (XIAP) to promote survival of Epstein-Barr virus+ (EBV+) B cell lymphomas. J Biol Chem 2011: 286: 37368-37378.
73. Chen L, Monti S, Juszczynski P, et al., SYK-dependent tonic B-cell receptor signaling is a rational treatment target in diffuse large B-cell lymphoma. Blood 2008: 111: 2230-2237.
74. Buchner M, Fuchs S, Prinz G, et al., Spleen tyrosine kinase is overexpressed and represents a potential therapeutic target in chronic lymphocytic leukemia. Cancer Res 2009: 69: 5424-5432.
75. Buchner M, Baer C, Prinz G, et al., Spleen tyrosine kinase inhibition prevents chemokine- and integrin-mediated stromal protective effects in chronic lymphocytic leukemia. Blood 2010: 115: 4497-4506.
76. Quiroga MP, Balakrishnan K, Kurtova AV, et al., B-cell antigen receptor signaling enhances chronic lymphocytic leukemia cell migration and survival: Specific targeting with a novel spleen tyrosine kinase inhibitor, R406. Blood 2009: 114: 1029-1037.
77. Young RM, Hardy IR, Clarke RL, et al., Mouse models of non-Hodgkin lymphoma reveal Syk as an important therapeutic target. Blood 2009: 113: 2508-2516.
78. Suljagic M, Longo PG, Bennardo S, et al., The Syk inhibitor fostamatinib disodium (R788) inhibits tumor growth in the EÎ- TCL1 transgenic mouse model of CLL by blocking antigen-dependent B-cell receptor signaling. Blood 2010: 116: 4894-4905.
79. Friedberg JW, Sharman J, Sweetenham J, et al., Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia. Blood 2010: 115: 2578-2585.
80. Coopman PJ, Do MT, Barth M, et al., The Syk tyrosine kinase suppresses malignant growth of human breast cancer cells. Nature 2000: 406: 742-747.
81. Coopman PJ, Mueller SC,. The Syk tyrosine kinase: A new negative regulator in tumor growth and progression. Cancer Lett 2006: 241: 159-173.
82. Finetti P, Cervera N, Charafe-Jauffret E, et al., Sixteen-kinase gene expression identifies luminal breast cancers with poor prognosis. Cancer Res 2008: 68: 767-776.
83. Fan C, Oh DS, Wessels L, et al., Concordance among gene-expression-based predictors for breast cancer. N Engl J Med 2006: 355: 560-569.
84. Veer LV, Dai H, Van De Vijver M, et al., Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002: 415: 530-536.
85. Fruehling S, Swart R, Dolwick KM, et al., Tyrosine 112 of latent membrane protein 2A is essential for protein tyrosine kinase loading and regulation of Epstein-Barr virus latency. J Virol 1998: 72: 7796-7806.
86. Lombardo LJ, Lee FY, Chen P, et al., Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)-piperazin-1-yl)-2-methylpyrimidin-4-ylamino) thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. J Med Chem 2004: 47: 6658-6661.
87. Chang Q, Jorgensen C, Pawson T, et al., Effects of dasatinib on EphA2 receptor tyrosine kinase activity and downstream signalling in pancreatic cancer. Br J Cancer 2008: 99: 1074-1082.
88. Rajeshkumar NV, Tan AC, De Oliveira E, et al., Antitumor effects and biomarkers of activity of AZD0530, a Src inhibitor, in pancreatic cancer. Clin Cancer Res 2009: 15: 4138-4146.
89. Yang JC, Ok J-H, Busby JE, et al., Aberrant activation of androgen receptor in a new neuropeptide-autocrine model of androgen-insensitive prostate cancer. Cancer Res 2009: 69: 151-160.
90. Golas JM, Lucas J, Etienne C, et al., SKI-606, a Src/Abl inhibitor with in vivo activity in colon tumor xenograft models. Cancer Res 2005: 65: 5358-5364.
91. Messersmith WA, Rajeshkumar NV, Tan AC, et al., Efficacy and pharmacodynamic effects of bosutinib (SKI-606), a Src/Abl inhibitor, in freshly generated human pancreas cancer xenografts. Mol Cancer Ther 2009: 8: 1484-1493.
92. Aleshin A, Finn RS,. SRC: A century of science brought to the clinic. Neoplasia 2010: 12: 599-607.
93. Engelman JA, Luo J, Cantley LC,. The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat Rev Genet 2006: 7: 606-619.
94. Samuels Y, Wang Z, Bardelli A, et al., High frequency of mutations of the PIK3CA gene in human cancers. Science 2004: 304: 554.
95. Manning BD, Cantley LC,. AKT/PKB signaling: Navigating downstream. Cell 2007: 129: 1261-1274.
96. Courtney KD, Corcoran RB, Engelman JA,. The PI3K pathway as drug target in human cancer. J Clin Oncol 2010: 28: 1075-1083.
97. Markman B, Dienstmann R, Tabernero J,. Targeting the PI3K/Akt/mTOR pathway-beyond rapalogs. Oncotarget 2010: 1: 530-543.
98. Ihle NT, Lemos R, Wipf P, et al., Mutations in the phosphatidylinositol- 3-kinase pathway predict for antitumor activity of the inhibitor PX-866 whereas oncogenic Ras is a dominant predictor for resistance. Cancer Res 2009: 69: 143-150.
99. Jimeno A, Herbst RS, Falchook GS, et al., Final results from a phase I, dose-escalation study of PX-866, an irreversible, pan-isoform inhibitor of PI3 kinase. J Clin Oncol 2010: 28 (15 Suppl): Abstract 3089.
100. Shapiro G, Kwak E, Baselga J, et al., Phase I dose-escalation study of XL147, a PI3K inhibitor administered orally to patients with solid tumors. J Clin Oncol 2009: 27 (146 Suppl): Abstract 3500.
101. Maira M, Menezes D, Pecchi S, et al., NVP-BKM120, a novel inhibitor of phosphoinosotide 3-kinase in Phase I/II clinical trials, shows significant antitumor activity in xenograft and primary tumor models. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC; Philadelphia, PA: AACR, 2010. Abstract 4497.
102. Voliva CF, Pecchi S, Burger M, et al., Biological characterization of NVP-BKM120, a novel inhibitor of phosphoinosotide 3-kinase in Phase I/II clinical trials. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC; Philadelphia, PA: AACR, 2010. Abstract 4498.
103. Baselga J, De Jonge MJ, Rodon J, et al., A first-in-human phase I study of BKM120, an oral pan-class I PI3K inhibitor, in patients (pts) with advanced solid tumors. J Clin Oncol 2010: 28 (15 Suppl): Abstract 3003.
104. Von Hoff DD, Lorusso P, Tibes R, et al., A first-in-human phase I study to evaluate the pan-PI3K inhibitor GDC-0941 administered QD or BID in patients with advanced solid tumors. J Clin Oncol 2010: 28 (15 Suppl): Abstract 2541.
105. Herman SEM, Gordon AL, Wagner AJ, et al., Phosphatidylinositol 3-kinase-Î inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals. Blood 2010: 116: 2078-2088.
106. Lannutti BJ, Meadows SA, Herman SEM, et al., CAL-101, a p110delta selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability. Blood 2011: 117: 591-594.
107. Furman RR, Byrd JC, Flinn IW, et al., Interim results from a phase I study of CAL-101, a selective oral inhibitor of phosphatidylinositol 3-kinase p110d isoform, in patients with relapsed or refractory hematologic malignancies. J Clin Oncol 2010: 28 (15 Suppl): Abstract 3032.
108. Hirai H, Sootome H, Nakatsuru Y, et al., MK-2206, an allosteric Akt inhibitor, enhances antitumor efficacy by standard chemotherapeutic agents or molecular targeted drugs in vitro and in vivo. Mol Cancer Ther 2010: 9: 1956-1967.
109. Yap TA, Patnaik A, Fearen I, et al., First-in-class phase I trial of a selective Akt inhibitor, MK2206 (MK), evaluating alternate day (QOD) and once weekly (QW) doses in advanced cancer patients (pts) with evidence of target modulation and antitumor activity. J Clin Oncol 2010: 28 (15 Suppl): Abstract 3009.
110. Garlich JR, De P, Dey N, et al., A vascular targeted pan phosphoinositide 3-kinase inhibitor prodrug, SF1126, with antitumor and antiangiogenic activity. Cancer Res 2008: 68: 206-215.
111. Mahadevan D, Chiorean EG, Harris W, et al., Phase I study of the multikinase prodrug SF1126 in solid tumors and B-cell malignancies. J Clin Oncol 2011: 29: Abstract 3015.
112. Maira S-M, Stauffer F, Brueggen J, et al., Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity. Mol Cancer Ther 2008: 7: 1851-1863.
113. Serra V, Markman B, Scaltriti M, et al., NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations. Cancer Res 2008: 68: 8022-8030.
114. Burris H, Rodon J, Sharma S, et al., First-in-human phase I study of the oral PI3K inhibitor BEZ235 in patients (pts) with advanced solid tumors. J Clin Oncol 2010: 28 (15 Suppl): Abstract 3005.
115. Prasad G, Sottero T, Yang X, et al., Inhibition of PI3K/mTOR pathways in glioblastoma and implications for combination therapy with temozolomide. Neuro Oncol 2011: 13: 384-392.
116. Brana I, Lorusso P, Baselga J, et al., A phase I dose-escalation study of the safety, pharmacokinetics (PK), and pharmacodynamics of XL765 (SAR245409), a PI3K/TORC1/TORC2 inhibitor administered orally to patients (pts) with advanced malignancies. J Clin Oncol 2010: 28 (15 Suppl): Abstract 3030.